Acute Transverse Myelopathy Probably Related to Intravenous Gemcitabine Plus Cisplatin
Meizuo Zhong,Bin Li,Jing Li
DOI: https://doi.org/10.1345/aph.1p674
IF: 3.4628
2011-01-01
Annals of Pharmacotherapy
Abstract:TO THE EDITOR: Acute transverse myelopathy, definedas the developmentof isolated spinal corddysfunction over hoursor days, is a relatively uncommon sequela following intrathecal administration of chemotherapyor chemoradiationtherapy,' Gemcitabineplus cisplatin has been recommended by the National Comprehensive Cancer Networkas first-line chemotherapy in patients withadvanced squamous cell lungcancer. Recently, 2 casesof reversible posterior leukoencephalopathy syndrome(RPLS) inducedby gemcitabinelcisplatin have beenreported.P Wedescribethe association of intravenous administration of this drug combination with acute transverse myelopathy in a patientwith lungcancer. Case Report. A 45-year-old male diagnosed with stage I1IB squamous cell lung cancer was scheduled to receive 2 cycles of gemcitabine/cisplatin. He had been healthy,withoutpulmonarydisease, before diagnosis.Resultsof bloodcell count, as well as liver and kidneyfunction, were normal and the resultof test for hepatitisviruswas negative. Hydration and antiemetics (metoclopramide and ondansetron) were administered to preventchemotherapy-induced nephrotoxicity and nausea. No over-the-counter products or herbalmedications weregiven.Following I cycleof chemotherapy (gemcitabine 1000 mg/rrf on days I and 8 and cisplatin 75 mg/m' on day I of each 21-day cycle), the patient's coughabated.However, he experienced National Cancer Institute CommonTerminology Criteriafor AdverseEventsv3.0grade2 neutropenia and grade 3 thrombocytopenia, which resolvedafter use of granulocyte colony-stimulating factor and recombinant human thrombopoietin. There was no significantvomiting.Before the second cycle of chemotherapy, the patienthada slightcough,but all laboratory test results were with normal limits.He received the same chemotherapy and hydration but no antiemetics. On day 9, he complained of lossof sensitivity to lighttouchin bothof his lowerextremities.Neitherfocal neurologic signs nor pathologicreflexeswere noted.GP-related peripheral nerve impairment was suspected; thus,he wasdischarged home.The numbness worsened,and 3 days laterhe experienced paraplegia and paresthesia from the waistdown,accompanied by urinary retention and difficult defecation. He was readmitted to thehospital. Neurologic examination indicatedweakness in the lowerextremities (MRCgrade I ).4Sensations of pain, temperature, position, and vibration werealmostabsentbelowtheT6 level.Kneejerk reflexwas presentand Babinskisigns were positive. Laboratory examination demonstrated no evidence of tumorlysissyndrome or paraneoplastic syndrome. Brainmagnetic resonance imaging(MRI)exhibited no abnormalities. Lumbar puncturerevealed slightly elevated protein levels in the cerebrospinal fluid;results of cultureswere negative. Whole-spine MRI(Figure I) was suggestive of nonspecific myelopathy,possibly associated with the intravenous administration of gemcitabine/cisplatin. Accordingly, the chemotherapy was discontinued. Methylprednisolone 1000 mg/day, antiemetics, and gastrointestinal protectants were administered. Subsequently, the doseof methylprednisolone was reducedby 50% every 3 days. One month later, the symptoms improved, with voluntary micturition,muscle force recoveringto MRC grade 2-3, and improvementof sensation. However, the difficulty in defecation persisted. Lung computedtomography indicated no augmentation of the primarylesion. An objective causality assessment revealed that gemcitabine/cisplatin was the probable causeof this adverse reaction.' Discussion.Gemcitabine is a nucleoside analogue, similarin structure to cytarabine. Cytarabine-related myelopathy has beencloselyassociated with direct neurotoxicity and some typesof allergicresponsesj-' In the only report of cisplatin-induced myelopathy, the histologyrevealed ischemic necrosismyelopathy resulting fromfocal small-vessel thrombosis ratherthandirectneurotoxicity," Recently, somecasesof chemotherapy-related RPLShave been reported. The suggested pathophysiology includes a breakdownin vascularautoregulation, the cytotoxiceffectson the vascular endothelium, and an immunemechanism. Autopsies revealing vacuolar demyelination and ischemia in boththespinal cord andsubcortical white mailersuggestthat the pathogenesis of chemotherapy-relatedmyelopathy may be similarto thatof RPLS.9.10 Gemcitabine and cisplatin are commonly usedfor chemotherapy. The majoradverseeffectsare gastrointestinal reactions,myelosuppression, andnephrotoxicity. Neurotoxicity induced by thedrugcombination is infrequent, and mostneurotoxicity is causedby peripheral nervelesions of extremity paresthesia." To our knowledge, this is the first case of myelopathy that was probably induced by the intravenous administration of gemcitabine/cisplatin withoutaccompanying intrathecal chemotherapyor radiotherapy. Clinicians shouldbe awareof the possibility of severespinalcord lesions associatedwith the intravenous administration of chemotherapy, especially gemcitabine or cisplatin. Quickrecognition, discontinuation of thecausative medication, and earlymanagement may reverse theclinical manifestations of thesyndrome.